These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11474780)

  • 1. Systemic delivery of cetrorelix to rats by a new aerosol delivery system.
    Lizio R; Klenner T; Sarlikiotis AW; Romeis P; Marx D; Nolte T; Jahn W; Borchard G; Lehr CM
    Pharm Res; 2001 Jun; 18(6):771-9. PubMed ID: 11474780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic delivery of the GnRH antagonist cetrorelix by intratracheal instillation in anesthetized rats.
    Lizio R; Klenner T; Borchard G; Romeis P; Sarlikiotis AW; Reissmann T; Lehr CM
    Eur J Pharm Sci; 2000 Jan; 9(3):253-8. PubMed ID: 10594381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel formulations of cetrorelix acetate in healthy men: pharmacodynamic effects and noncompartmental pharmacokinetics.
    Erb K; Junge K; Pechstein B; Schneider E; Derendorf H; Hermann R
    J Clin Pharmacol; 2002 Sep; 42(9):995-1001. PubMed ID: 12211225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary delivery of detirelix by intratracheal instillation and aerosol inhalation in the briefly anesthetized dog.
    Bennett DB; Tyson E; Nerenberg CA; Mah S; de Groot JS; Teitelbaum Z
    Pharm Res; 1994 Jul; 11(7):1048-55. PubMed ID: 7937547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition and metabolism of cetrorelix, a potent luteinizing hormone-releasing hormone antagonist, in rats and dogs.
    Schwahn M; Schupke H; Gasparic A; Krone D; Peter G; Hempel R; Kronbach T; Locher M; Jahn W; Engel J
    Drug Metab Dispos; 2000 Jan; 28(1):10-20. PubMed ID: 10611134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats.
    Horvath JE; Toller GL; Schally AV; Bajo AM; Groot K
    Proc Natl Acad Sci U S A; 2004 Apr; 101(14):4996-5001. PubMed ID: 15044692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective suppression of luteinizing hormone and testosterone by single doses of the new gonadotropin-releasing hormone antagonist cetrorelix (SB-75) in normal men.
    Behre HM; Klein B; Steinmeyer E; McGregor GP; Voigt K; Nieschlag E
    J Clin Endocrinol Metab; 1992 Aug; 75(2):393-8. PubMed ID: 1639941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GnRH antagonist cetrorelix prevents sexual maturation of peripubertal male rats.
    Roth C; Leonhardt S; Seidel C; Lakomek M; Wuttke W; Jarry H
    Exp Clin Endocrinol Diabetes; 2000; 108(5):358-63. PubMed ID: 10989955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats.
    Pinski J; Lamharzi N; Halmos G; Groot K; Jungwirth A; Vadillo-Buenfil M; Kakar SS; Schally AV
    Endocrinology; 1996 Aug; 137(8):3430-6. PubMed ID: 8754771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of testosterone suppression in young men by the gonadotropin releasing hormone antagonist cetrorelix on plasma lipids, lipolytic enzymes, lipid transfer proteins, insulin, and leptin.
    Büchter D; Behre HM; Kliesch S; Chirazi A; Nieschlag E; Assmann G; von Eckardstein A
    Exp Clin Endocrinol Diabetes; 1999; 107(8):522-9. PubMed ID: 10612483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a new aerosol delivery system for systemic pulmonary delivery in anaesthetized and orotracheal intubated rats.
    Lizio R; Marx D; Nolte T; Lehr CM; Sarlikiotis AW; Borchard G; Jahn W; Klenner T
    Lab Anim; 2001 Jul; 35(3):261-70. PubMed ID: 11459412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic/pharmacodynamic modeling of cetrorelix, a novel LH-RH antagonist, and testosterone in rats and dogs.
    Schwahn M; Nagaraja NV; Derendorf H
    Pharm Res; 2000 Mar; 17(3):328-35. PubMed ID: 10801222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-temperature micronization of a peptide drug in fluid propellant: case study cetrorelix.
    Lizio R; Damm M; Sarlikiotis AW; Bauer HH; Lehr CM
    AAPS PharmSciTech; 2001 Jul; 2(3):E12. PubMed ID: 14727871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the gonadotropin-releasing hormone antagonist cetrorelix in the early postimplantation period on rat pregnancy.
    Tug N; Uslu U; Cumbul A; Eyuboglu S; Cam C; Karateke A; Yilmaz B
    Eur J Obstet Gynecol Reprod Biol; 2011 Apr; 155(2):166-70. PubMed ID: 21242023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-ranging study of the luteinizing hormone-releasing hormone receptor antagonist cetrorelix pamoate in the treatment of patients with symptomatic benign prostatic hyperplasia.
    Debruyne F; Tzvetkov M; Altarac S; Geavlete PA
    Urology; 2010 Oct; 76(4):927-33. PubMed ID: 20932411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative morphometric analysis of pulmonary deposition of aerosol particles inhaled via intratracheal nebulization, intratracheal instillation or nose-only inhalation in rats.
    Leong BK; Coombs JK; Sabaitis CP; Rop DA; Aaron CS
    J Appl Toxicol; 1998; 18(2):149-60. PubMed ID: 9570698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of detirelix following intratracheal instillation and aerosol inhalation in the unanesthetized awake sheep.
    Schreier H; McNicol KJ; Bennett DB; Teitelbaum Z; Derendorf H
    Pharm Res; 1994 Jul; 11(7):1056-9. PubMed ID: 7937548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic effects and plasma pharmacokinetics of single doses of cetrorelix acetate in healthy premenopausal women.
    Erb K; Klipping C; Duijkers I; Pechstein B; Schueler A; Hermann R
    Fertil Steril; 2001 Feb; 75(2):316-23. PubMed ID: 11172833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained suppression of serum LH, FSH and testosterone and increase of high-density lipoprotein cholesterol by daily injections of the GnRH antagonist cetrorelix over 8 days in normal men.
    Behre HM; Böckers A; Schlingheider A; Nieschlag E
    Clin Endocrinol (Oxf); 1994 Feb; 40(2):241-8. PubMed ID: 8137524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delivery of Peptidic Gonadotropin Releasing Hormone Antagonists.
    AlSheyyab RY; Al-Taani BM; Obeidat RM; Alsmadi MM; Masaedeh RK; Sabat RN
    Curr Drug Deliv; 2018; 15(5):602-609. PubMed ID: 29446744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.